<bill session="115" type="s" number="2691" updated="2019-07-16T21:20:11Z">
  <state datetime="2018-04-17">REFERRED</state>
  <status>
    <introduced datetime="2018-04-17"/>
  </status>
  <introduced datetime="2018-04-17"/>
  <titles>
    <title type="official" as="introduced">A bill to hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic in the United States.</title>
    <title type="short" as="introduced">Opioid Crisis Accountability Act of 2018</title>
    <title type="short" as="introduced">Opioid Crisis Accountability Act of 2018</title>
    <title type="display">Opioid Crisis Accountability Act of 2018</title>
  </titles>
  <sponsor bioguide_id="S000033"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2018-04-19"/>
    <cosponsor bioguide_id="G000555" joined="2018-04-19"/>
    <cosponsor bioguide_id="H001075" joined="2018-04-17"/>
  </cosponsors>
  <actions>
    <action datetime="2018-04-17">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2018-04-17" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="115" relation="identical" number="5782"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business ethics"/>
    <term name="Business expenses"/>
    <term name="Business records"/>
    <term name="Child health"/>
    <term name="Civil actions and liability"/>
    <term name="Corporate finance and management"/>
    <term name="Department of Health and Human Services"/>
    <term name="Department of Justice"/>
    <term name="Department of Labor"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Education programs funding"/>
    <term name="Elementary and secondary education"/>
    <term name="Employment taxes"/>
    <term name="Executive agency funding and structure"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Government trust funds"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Income tax credits"/>
    <term name="Marketing and advertising"/>
    <term name="Medical research"/>
    <term name="Preschool education"/>
    <term name="Prescription drugs"/>
    <term name="Research and development"/>
    <term name="Securities"/>
    <term name="Small business"/>
    <term name="Wages and earnings"/>
  </subjects>
  <amendments/>
  <summary date="2018-04-17T04:00:00Z" status="Introduced in Senate">Opioid Crisis Accountability Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.

The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2)revoking any remaining period of market exclusivity for such product, (3)requiring reimbursement of federal funding received for such product, and (4)prohibiting certain tax credits.</summary>
  <committee-reports/>
</bill>
